FDA accepts supplemental NDA for DUREZOL by SANDOZ
The FDA has accepted the supplemental NDA for DUREZOL (difluprednate) submitted by SANDOZ, with a standard review priority.
Asset / Drug
Drug and asset intelligence for DUREZOL with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.